Open AccessAbstract CT272: Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent or adjuvant setting
Author(s) -
Barbara O’Brien,
Carlos Kamiya-Matsuoka,
Shiao-Pei Weathers,
Alfred Yung,
Monica Loghin,
Rebecca Harrison,
Nazanin Majd,
Jeffrey Bacha,
Dennis Brown,
Anne Steinø,
Gregory R. Johnson,
Sarath Kanekal,
John Langlands,
Lorena M. Lopez,
Richard Schwartz,
Marta PenasPrado,
John F. de Groot
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct272
Subject(s) - temozolomide , bevacizumab , medicine , oncology , adjuvant , adjuvant therapy , phases of clinical research , cancer , radiation therapy , cancer research , clinical trial , chemotherapy